Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia
Fibromyalgia, Sleep, Chronic Pain
About this trial
This is an interventional treatment trial for Fibromyalgia
Eligibility Criteria
Inclusion Criteria: Each patient must fulfill the diagnosis criteria of fibromyalgia according to the American College of Rheumatology Based on patient's information: The patient must complain of unrefreshing sleep for at least 3 nights per week over the past month. The patient spends at least 6.5 hours and not more than 9 hours, in bed, each night over the past 2 weeks. Female patients of childbearing potential must have a confirmed negative pregnancy test at the end of the screening period and use an acceptable method of birth control throughout the study Written, signed and dated informed consent must be obtained from each patient Willing to abstain from taking any medication or treatment prohibited as per the protocol Exclusion Criteria: Females who are lactating or pregnant Night shift workers, and individuals who nap 3 or more times per week over the preceding month (nap: intentionally sleeping for more than 20 minutes during the day). Consumption of beverage with caffeine (i.e. tea, coffee, or cola) comprising more than 2 cups or glasses per day Past or Current medical history of any significant, severe, or unstable acute or chronically progressive medical or surgical disorder which may affect patient safety
Sites / Locations
- Radiant Research
- San Diego Arthritis Medical Clinic
- Jacksonville Center for Clinical Research
- Miami Research Assoc., Inc.
- Renstar Medical Research
- Comprehensive Neuroscience
- Physicians Research Group
- Wichita Clinic PA
- Westroads Medical Group
- Physicians Research Options
- Seattle Rheumatology Assoc.
- Sanofi-Aventis Administrative Office
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
1
2
3
1 mg daily
5 mg daily